Dupixent (dupilumab) is most commonly dosed as a 300 mg subcutaneous injection every two weeks for adults, but the actual regimen depends on the condition being treated, the patient’s body weight, and in some cases their age. The standard every-two-week schedule applies to moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps in adults, but pediatric patients often receive weight-tiered doses, and the first injection is typically a double “loading” dose. The details get more nuanced than a single number, and those nuances matter for both effectiveness and cost.
Standard Adult Regimens by Condition
For adults with moderate-to-severe atopic dermatitis, the approved regimen is a 600 mg loading dose (given as two 300 mg injections on day one), followed by 300 mg every two weeks. This same every-two-week cadence applies to adults with moderate-to-severe asthma added on to existing controller therapy, where a pivotal trial enrolled patients on 300 mg every two weeks for 24 weeks.1PubMed. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma Chronic rhinosinusitis with nasal polyps follows the same 300 mg every-two-week pattern. For eosinophilic esophagitis in adults and adolescents weighing at least 40 kg, the approved dose is 300 mg once weekly, making it the only indication where Dupixent is injected that frequently.
Asthma dosing has one wrinkle worth knowing about. For patients who do not also have atopic dermatitis or eosinophilic esophagitis and who do not require oral corticosteroids, a lower dose of 200 mg every two weeks (with a 400 mg loading dose) is an option. In practice, many prescribers default to the 300 mg dose because it covers all potential overlap conditions, but the 200 mg regimen exists for a narrower asthma-only population.
Why Pediatric Doses Are Weight-Tiered
Children do not simply get a smaller version of the adult dose. Because the drug’s clearance scales with body weight, pediatric dosing is split into tiers that change as the child grows. In trials of children aged 6 to 11 with severe atopic dermatitis, those weighing 15 to under 30 kg received 100 mg every two weeks (with a 200 mg loading dose), while those at 30 kg and above received 200 mg every two weeks (with a 400 mg loading dose). A separate arm tested 300 mg every four weeks regardless of weight.2Journal of the American Academy of Dermatology. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis
Based on pharmacokinetic modeling across these trials, researchers proposed a refined weight-tiered approach: for adolescents, 200 mg every two weeks if they weigh 30 to under 60 kg, and 300 mg every two weeks at 60 kg or above. For younger children, the proposal was 300 mg every four weeks for those 15 to under 30 kg, and 200 mg every two weeks for those 30 to under 60 kg.3PubMed Central. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis The logic is straightforward: a lighter child clears the drug more slowly relative to the dose, so less drug is needed to hit the same blood levels. A phase 2 study in children under age 6 confirmed that drug exposure increased more than expected relative to dose, reinforcing why weight-based adjustments matter in younger patients.4PubMed Central. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis
Population pharmacokinetic analyses in eosinophilic esophagitis tell a similar story: body weight was the most important factor influencing how fast the drug is cleared, while age by itself did not matter once weight was accounted for.5PubMed Central. Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis If your child’s weight changes significantly between appointments, it is worth flagging this with the prescriber, because crossing a weight threshold could mean a dose adjustment.
The Purpose of Loading Doses
Almost every Dupixent regimen starts with a loading dose that is double the maintenance dose. For the 300 mg every-two-week adult eczema regimen, that means 600 mg on day one. For the 200 mg asthma regimen, it is 400 mg. The reason comes down to how monoclonal antibodies behave in the body. Dupilumab has a bioavailability of about 61% when injected under the skin, meaning roughly four out of every ten milligrams never reach the bloodstream.6PubMed Central. Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Rα, in Atopic Dermatitis Patients and Normal Volunteers Combined with a half-life of roughly two to three weeks, this means it takes several doses before blood levels reach a stable plateau. The loading dose essentially front-loads the drug to get closer to that plateau on day one rather than week six.
A dose-ranging trial in adults with atopic dermatitis showed that effectiveness measures generally improved with higher trough concentrations, and the benefit plateaued around the levels achieved by the 300 mg every-two-week regimen.7PubMed Central. Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis Skipping or delaying the loading dose would not be dangerous, but it would mean spending more weeks in a sub-therapeutic range before the drug builds up to effective levels.
How Dupilumab Is Cleared From the Body
Understanding how the drug disappears from your bloodstream helps explain some of the dosing quirks. Dupilumab has two elimination pathways running in parallel. One is a steady, predictable process where the body breaks down the antibody at a constant rate. The other is “target-mediated,” meaning the drug gets consumed as it binds to and is internalized with its target receptor, IL-4Rα. At lower blood concentrations, that target-mediated pathway dominates, which means the drug vanishes faster when there is less of it around.8PubMed Central. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
This nonlinear clearance has practical implications. If you miss a dose and your blood level drops into that lower range, the drug gets cleared even faster, creating a steeper decline than you might expect from the half-life alone. It also explains why doubling the dose does not simply double the blood level: at higher concentrations, the target-mediated pathway is already saturated, so extra drug sticks around longer than expected.
Can You Stretch the Dosing Interval?
One of the more practically interesting questions for long-term Dupixent users is whether they can eventually inject less often. The short answer: some patients can, but it is not a universal option, and there is no consensus guideline on how to do it safely.
In a study of adult atopic dermatitis patients, 11 out of 52 extended their injection interval to every three or four weeks after roughly a year of standard dosing. These patients had already achieved well-controlled disease, with low severity scores at the time of the switch. Over an average follow-up of about 14 months, their disease severity scores and IgE levels stayed in a controlled range, though eosinophil counts were more variable.9PubMed Central. Appropriate Injection Intervals of Dupilumab in Patients With Adult Atopic Dermatitis The study was small and observational, so it should not be read as proof that everyone can taper. But it suggests that for well-controlled patients, extending the interval is at least plausible.
Similar findings have emerged for chronic rhinosinusitis with nasal polyps. In a five-year real-world study, about 40% of patients extended their dosing intervals without losing control of their symptoms, and those patients also reported fewer side effects.10PubMed Central. Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes A broader review of the evidence across conditions has noted that a “large patient population” appears able to maintain disease control on a prolonged interval, though clinical predictors of who can do this successfully are still being worked out.
If you are interested in extending your injection interval, the general approach seen in these studies was cautious: patients had been stable on standard dosing for roughly a year, their disease severity was low, and the switch was made under medical supervision with monitoring. Unilaterally stretching doses without your prescriber’s input risks letting blood levels drop into the range where target-mediated clearance accelerates the decline, potentially triggering a flare that takes weeks to recover from.
Biomarkers That Predict Response in Asthma
Dupixent’s asthma dosing is the same regardless of your biomarker levels, but those levels strongly predict how much benefit you are likely to get. Fractional exhaled nitric oxide (FeNO) has emerged as a particularly useful predictor. In one analysis, the reduction in severe exacerbations compared with placebo was about 23% for patients with baseline FeNO below 25 parts per billion, about 58% for those with FeNO between 25 and 50, and about 69% for those with FeNO at 50 or above. These differences held independently of blood eosinophil counts.11PubMed. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma
In children with asthma, the picture is similar. Higher baseline eosinophil counts or FeNO levels predicted a greater reduction in exacerbations with dupilumab. Patients with either elevated FeNO or elevated eosinophil counts showed a clinical response, and the two biomarkers independently added predictive value.12PubMed. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma This does not mean the drug fails entirely in patients with lower biomarker levels, but the magnitude of benefit is noticeably smaller. For someone whose FeNO is consistently low and whose eosinophil counts are normal, the conversation with a prescriber about whether Dupixent is worth the cost and injection burden becomes more nuanced.
Anti-Drug Antibodies and What They Mean for Dosing
Your immune system can sometimes produce antibodies against dupilumab itself, called anti-drug antibodies (ADAs). This happens with most biologic medications to some degree, and in most patients who develop them, the antibodies are low-level and do not meaningfully affect the drug’s performance. Across adult and pediatric atopic dermatitis trials, effectiveness was generally similar between patients who were ADA-positive and those who were ADA-negative.13PubMed Central. Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
The exception is high-titer ADAs, which were uncommon but associated with lower dupilumab blood levels and reduced effectiveness. Even among those patients, titers tended to decrease and effectiveness improved over time with continued treatment.14PubMed Central. Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis In rare cases, high-titer ADAs led to significant clinical consequences: one patient developed serum sickness and had to stop the drug. But the overall message is reassuring. Most patients never develop ADAs, most who do develop them at low levels that do not interfere with treatment, and stopping the drug solely because of a positive ADA test would be premature in the absence of clinical worsening.
How the Delivery Devices Compare
Dupixent comes in prefilled syringes and autoinjectors, and both are available in 200 mg and 300 mg strengths. The practical question most patients have is whether the device type matters for how well the drug works. A pharmacokinetic comparison showed that the 200 mg autoinjector delivered comparable drug exposure to the 200 mg prefilled syringe, with no differences in the safety profile between the two devices.15PubMed Central. Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe Choice between them is largely about preference: the autoinjector is generally easier for self-injection and requires less manual dexterity, while the syringe gives more control over injection speed. Caregivers administering doses to children may prefer the syringe for smaller-volume injections. Either way, the drug gets to the same place.
Real-World Adherence Patterns
Sticking to a biweekly injection schedule at home sounds straightforward, but real-world data paints a more complicated picture. In a study of patients self-injecting Dupixent for various allergic conditions, about 86% successfully performed self-injection, and roughly 71% hit their scheduled injection dates consistently. Adherence declined the longer patients were on the drug, which is a common pattern with self-administered biologics. Interestingly, age, sex, the underlying disease, and the type of injection device did not predict adherence; duration of therapy was the factor that mattered.16PubMed Central. Barrier Factors of Adherence to Dupilumab Self-Injection for Severe Allergic Disease
A US claims analysis of patients with chronic rhinosinusitis with nasal polyps found that about 75% met a standard adherence threshold over 12 months. Among those who stayed on the drug for at least a year, 94% were adherent during that period.17Journal of Allergy and Clinical Immunology: Global. Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab That gap between the overall population and the persistent subset hints at the real issue: a meaningful fraction of patients stop the drug within the first year altogether, and those who stick with it tend to be quite consistent.
When compared to other self-administered asthma biologics, dupilumab actually showed the lowest proportion of days covered and the highest average delays between doses.18PubMed. Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results This may partly reflect its home-administration model (some competing biologics are given in clinics, where adherence is structurally easier) and partly the biweekly frequency. Missing one clinic appointment is a bigger psychological event than skipping a home injection by a few days.
Therapeutic Drug Monitoring
For most patients, Dupixent dosing is straightforward: you follow the label regimen and assess how you are doing clinically. But researchers have started exploring whether measuring blood levels of the drug could help fine-tune decisions, especially for patients who are not responding well or who want to extend their dosing interval. A two-center study of 149 atopic dermatitis patients found that dupilumab blood levels varied widely between patients but were fairly consistent within the same patient over time. Higher early levels were modestly predictive: at two weeks, a level at or above about 64 micrograms per milliliter predicted well-controlled eczema at 24 weeks with perfect specificity but only 60% sensitivity. At 12 weeks, levels below about 33 micrograms per milliliter predicted inadequate control at 24 weeks.19PubMed. The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis
These thresholds are not yet used in routine clinical practice, and no dosing guideline currently recommends routine blood level monitoring. But for a patient who is doing poorly on standard dosing, a very low drug level might suggest that the issue is pharmacokinetic (perhaps high-titer anti-drug antibodies are clearing the drug faster, or adherence has been inconsistent) rather than a true failure to respond to the drug’s mechanism. That distinction matters, because the management steps are very different.
Safety in Patients With Serious Comorbidities
Clinical trials tend to exclude people with active cancers, organ failure, or chronic infections, leaving a gap in knowledge about whether the drug is safe in medically complex patients. An observational study followed 70 patients with moderate-to-severe atopic dermatitis who also had conditions like cancer, kidney or liver failure, chronic viral infections, and neurological disorders over three years of dupilumab treatment. The safety profile was comparable to what trials and real-world data showed in healthier patients.20PubMed Central. Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations This is a small, observational dataset, so it does not carry the weight of a randomized trial, but it is reassuring for patients and prescribers who have been hesitant to start the drug because of other health problems.
Pregnancy and Newborn Considerations
Dupilumab has no formal pregnancy category under current labeling systems, and data on its use during pregnancy remain limited to case reports and registry entries. No controlled trials have been conducted in pregnant women. What is known comes from the biology of monoclonal antibodies in general: they are actively transported across the placenta, especially during the second and third trimesters. Because of that transfer, newborns exposed to dupilumab later in pregnancy may carry detectable drug levels at birth, which raises a specific practical concern about vaccination. Live vaccines should be avoided in these infants for at least six months after delivery, or until the drug is no longer detectable in their blood.21PubMed Central. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature Inactivated vaccines are not affected by this concern.
For women planning pregnancy, the decision about whether to continue Dupixent involves weighing the risk of uncontrolled disease against the limited but growing safety data. This is a conversation best had with both a dermatologist (or allergist) and an obstetrician, ideally before conception rather than after a positive test.
When a Dose Gets Missed
The manufacturer’s guidance is to inject the missed dose as soon as possible and then resume the regular schedule from there. Given the drug’s half-life of roughly two to three weeks, being a few days late on a biweekly injection is unlikely to cause a dramatic drop in blood levels. But because of the nonlinear clearance described earlier, letting levels fall too far means the drug gets consumed faster, creating a steeper drop than the half-life alone would suggest. A single late injection is usually not a crisis. Multiple consecutively delayed injections, though, can let levels fall into that faster-clearance zone and risk a disease flare. Setting a phone reminder is unglamorous advice, but the adherence data suggest it is genuinely useful: most adherence failures are not about rejecting the drug but about the logistical friction of a home injection schedule over months and years.